Company Registration No. 13672560 (England and Wales)
DQS Medizinprodukte UK Limited
Financial statements
for the year ended 31 December 2024
Pages for filing with the registrar
DQS Medizinprodukte UK Limited
Contents
Page
Statement of financial position
1
Notes to the financial statements
2 - 7
DQS Medizinprodukte UK Limited
Statement of financial position
As at 31 December 2024
1
2024
2023
as restated
and unaudited
Notes
£
£
£
£
Fixed assets
Tangible assets
4
7,937
2,538
Current assets
Debtors
5
41,899
120,202
Creditors: amounts falling due within one year
6
(844,513)
(37,311)
Net current (liabilities)/assets
(802,614)
82,891
Net (liabilities)/assets
(794,677)
85,429
Capital and reserves
Called up share capital
90,000
90,000
Other reserves
650,244
650,244
Profit and loss reserves
(1,534,921)
(654,815)
Total equity
(794,677)
85,429

The director of the company has elected not to include a copy of the income statement within the financial statements.true

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 23 June 2026 and are signed on its behalf by:
S Hoffmann
Director
Company Registration No. 13672560
DQS Medizinprodukte UK Limited
Notes to the financial statements
For the year ended 31 December 2024
2
1
Accounting policies
Company information

DQS Medizinprodukte UK Limited is a private company limited by shares incorporated in England and Wales. The registered office is Suite 002 Parkes House, Unit 5 Wallbrook Business Centre, Green Lane, Hounslow, London, United Kingdom, TW4 6NW.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

At 31 December 2024, the company had net current liabilities of £802,614 (2023 - net current assets £82,891). Included within creditors falling due within one year is £805,776 (2023 - intercompany asset position £104,924) owed to fellow group undertaking. The directors have received a letter of support from the fellow undertaking confirming that the balance will not be requested for repayment for a minimum of 12 months from the date of approval of these financial statements and ongoing support will be given where required. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and machinery
20% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.4
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

DQS Medizinprodukte UK Limited
Notes to the financial statements (continued)
For the year ended 31 December 2024
1
Accounting policies (continued)
3

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.5
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.6
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's statement of financial position when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

DQS Medizinprodukte UK Limited
Notes to the financial statements (continued)
For the year ended 31 December 2024
1
Accounting policies (continued)
4
Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future paymen ts discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. A m ounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.7
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.8
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.9
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2
Critical accounting judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the director is required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

DQS Medizinprodukte UK Limited
Notes to the financial statements (continued)
For the year ended 31 December 2024
5
3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
7
4
4
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 January 2024
2,750
Additions
6,497
At 31 December 2024
9,247
Depreciation and impairment
At 1 January 2024
212
Depreciation charged in the year
1,098
At 31 December 2024
1,310
Carrying amount
At 31 December 2024
7,937
At 31 December 2023
2,538
5
Debtors
2024
2023
(restated)
Amounts falling due within one year:
£
£
Amounts owed by group undertakings
-
0
104,924
Other debtors
41,899
15,278
41,899
120,202
DQS Medizinprodukte UK Limited
Notes to the financial statements (continued)
For the year ended 31 December 2024
6
6
Creditors: amounts falling due within one year
2024
2023
(restated)
£
£
Trade creditors
30,604
6,796
Amounts owed to group undertakings
805,776
-
0
Taxation and social security
-
0
23,280
Other creditors
8,133
7,235
844,513
37,311
7
Audit report information

As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006.

The auditor's report is unqualified and includes the following:

Opinion

In our opinion the financial statements:

- give a true and fair view of the state of the company's affairs as at 31 December 2024 and of its loss for the year then ended;

- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and

- have been prepared in accordance with the requirements of the Companies Act 2006.

Senior Statutory Auditor:
Richard Walker ACA
Statutory Auditors:
Forrester Boyd Limited
Date of audit report:
25 June 2026
8
Prior period adjustment
Changes to the statement of financial position
As previously reported
Adjustment at 1 Jan 2023
Adjustment at 31 Dec 2023
As restated at 31 Dec 2023
£
£
£
£
Current assets
Debtors due within one year
15,278
2,125
102,799
120,202
Creditors due within one year
Other creditors
(438,192)
26,074
404,883
(7,235)
Net assets
(450,452)
28,199
507,682
85,429
Capital and reserves
Other reserves
-
-
650,244
650,244
Profit and loss reserves
(540,452)
28,199
(142,562)
(654,815)
Total equity
(450,452)
28,199
507,682
85,429
DQS Medizinprodukte UK Limited
Notes to the financial statements (continued)
For the year ended 31 December 2024
8
Prior period adjustment (continued)
7
Changes to the income statement
As previously reported
Adjustment
As restated
Period ended 31 December 2023
£
£
£
Administrative expenses
(431,370)
(114,363)
(545,733)
Loss for the financial period
(431,370)
(114,363)
(545,733)
Reconciliation of changes in equity
1 January
31 December
2023
2023
£
£
Adjustments to prior year
Write off of intercompany balance
28,199
22,126
Legal & professional fees
-
(120,847)
Computer running expenses
-
(243)
Insurance
-
(8,500)
Accountancy fees
-
(6,899)
Capital contribution
-
650,244
Total adjustments
28,199
535,881
Equity as previously reported
(47,281)
(450,452)
Equity as adjusted
(19,082)
85,429
Analysis of the effect upon equity
Other reserves
-
650,244
Profit and loss reserves
28,199
(114,363)
28,199
535,881
Reconciliation of changes in loss for the previous financial period
2023
£
Adjustments to prior year
Write off of intercompany balance
22,126
Legal & professional fees
(120,847)
Computer running expenses
(243)
Insurance
(8,500)
Accountancy fees
(6,899)
Total adjustments
(114,363)
Loss as previously reported
(431,370)
Loss as adjusted
(545,733)
2024-12-31 2024-01-01 false false false 25 June 2026 CCH Software CCH Accounts Production 2026.100 No description of principal activity Sigrid Uhlemann Dr C S Dyson H Von Mettenheim Rupert Dyson S Hoffman 13672560 2024-01-01 2024-12-31 13672560 2024-12-31 13672560 2023-12-31 13672560 core:OtherPropertyPlantEquipment 2024-12-31 13672560 core:OtherPropertyPlantEquipment 2023-12-31 13672560 core:WithinOneYear 2024-12-31 13672560 core:WithinOneYear 2023-12-31 13672560 core:ShareCapital 2024-12-31 13672560 core:ShareCapital 2023-12-31 13672560 core:OtherMiscellaneousReserve 2024-12-31 13672560 core:OtherMiscellaneousReserve 2023-12-31 13672560 core:RetainedEarningsAccumulatedLosses 2024-12-31 13672560 core:RetainedEarningsAccumulatedLosses 2023-12-31 13672560 bus:Director5 2024-01-01 2024-12-31 13672560 core:ComputerEquipment 2024-01-01 2024-12-31 13672560 2023-01-01 2023-12-31 13672560 core:OtherPropertyPlantEquipment 2023-12-31 13672560 core:OtherPropertyPlantEquipment 2024-01-01 2024-12-31 13672560 core:CurrentFinancialInstruments 2023-12-31 13672560 core:CurrentFinancialInstruments core:WithinOneYear 2024-12-31 13672560 core:CurrentFinancialInstruments core:WithinOneYear 2023-12-31 13672560 core:CurrentFinancialInstruments 2024-12-31 13672560 core:ContinuingOperations 2023-01-01 2023-12-31 13672560 bus:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 13672560 bus:SmallCompaniesRegimeForAccounts 2024-01-01 2024-12-31 13672560 bus:FRS102 2024-01-01 2024-12-31 13672560 bus:Audited 2024-01-01 2024-12-31 13672560 bus:Director1 2024-01-01 2024-12-31 13672560 bus:Director2 2024-01-01 2024-12-31 13672560 bus:Director3 2024-01-01 2024-12-31 13672560 bus:Director4 2024-01-01 2024-12-31 13672560 bus:FullAccounts 2024-01-01 2024-12-31 xbrli:pure xbrli:shares iso4217:GBP